Belzutifan + Zanzalintinib for Kidney Cancer

(LITESPARK-033 Trial)

This trial aims to determine if a combination of two drugs, belzutifan and zanzalintinib, can treat advanced kidney cancer more effectively than the current treatment, cabozantinib. Researchers seek to find out if this new treatment can extend patients' lives and prevent cancer progression. The trial targets individuals with advanced kidney cancer that has recurred after specific therapies. As a Phase 3 trial, it represents the final step before FDA approval, providing patients an opportunity to access potentially groundbreaking treatment.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Recent studies have shown that belzutifan is generally well-tolerated by patients. Common side effects include fatigue and dizziness, typically mild. Some patients experienced more serious side effects, such as low oxygen levels in the blood, but these were less common.

Early reports on zanzalintinib indicate a safety profile similar to other treatments in its category. Common side effects include nausea and diarrhea, with some patients experiencing increased blood pressure.

As this trial is in a later phase, researchers have already gathered substantial safety data. This data suggests that the combination of belzutifan and zanzalintinib is reasonably safe for further study. However, new side effects may still emerge, so all participants are closely monitored.

Researchers are excited about these treatments for kidney cancer because they offer new ways to tackle the disease. Belzutifan, combined with Zanzalintinib, targets a novel pathway in cancer cells, potentially improving outcomes by starving tumors of oxygen. Unlike traditional treatments like sunitinib or pazopanib, which focus on blocking blood vessel growth, this combination aims to directly disrupt tumor metabolism. Meanwhile, Cabozantinib, the comparator, is already known for its effectiveness in targeting specific cancer growth pathways, but the new combination could provide an even more effective approach. These advancements could lead to more effective and targeted treatment options for patients with kidney cancer.

This trial will compare the combination of belzutifan and zanzalintinib with cabozantinib for treating advanced kidney cancer. Research has shown that using belzutifan and zanzalintinib together may help treat this condition. One study found that patients taking this combination experienced longer periods of stable cancer and better treatment responses compared to those taking cabozantinib. Additionally, belzutifan alone improved conditions in 22% of kidney cancer patients. When zanzalintinib was combined with another drug, it showed a 63% response rate in advanced kidney cancer cases. These findings suggest that belzutifan and zanzalintinib together could effectively treat recurrent advanced kidney cancer.¹²³⁴⁵